8-K: American Shared Hospital Services Reports 17% Revenue Growth in Q1 2025 Driven by Expansion

American Shared Hospital Services (AMS) announced a 17% increase in revenue for Q1 2025, driven by strategic expansion and operational strength, particularly in direct patient services.

Summary

• American Shared Hospital Services reported a 17% increase in revenue for the first quarter of 2025, reaching $6.1 million compared to $5.2 million in the same period last year.
• The growth was primarily driven by the expansion of radiation therapy services.
• Direct patient services revenue saw a significant increase of 224%, reaching $3.1 million, due to the acquisition of Rhode Island centers and the new facility in Puebla, Mexico.
• Medical equipment leasing revenue decreased to $3.0 million from $4.3 million in the prior year quarter due to lower Gamma Knife and PBRT volumes.
• Total proton beam radiation therapy revenue decreased to $1.6 million from $2.6 million in the prior year quarter.
• Gross margin for Q1 2025 was $942,000, compared to $2.1 million in Q1 2024, primarily due to lower treatment volumes.
• The company reported a net loss attributable to American Shared Hospital Services of $625,000, or $0.10 per share, compared to a net income of $119,000, or $0.02 per diluted share for Q1 2024.
• Adjusted EBITDA was $0.9 million for Q1 2025, compared to $1.7 million in Q1 2024.
• Cash, cash equivalents, and restricted cash totaled $11.5 million as of March 31, 2025, compared to $11.3 million at December 31, 2024.
• Shareholders' equity was $24.6 million, or $3.82 per outstanding share, compared to $25.2 million, or $3.92 per outstanding share at the end of the previous year.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is strong, the net loss and decreased EBITDA raise concerns. Management's positive outlook and strategic initiatives provide some optimism.

Positives

• The company experienced a 17% increase in overall revenue, indicating growth in its core business.
• The direct patient services segment saw substantial growth of 224%, driven by strategic acquisitions and new facilities.
• The company's linear accelerator business reported $2.4 million in revenue for Q1 2025 compared to zero in Q1 2024, showcasing successful diversification.
• The company has $11.5 million in cash, cash equivalents, and restricted cash.
• The company is exploring additional tuck-in acquisition opportunities and anticipates closing on one this fiscal year.
• The company has received Certificate of Need approvals for new radiation therapy treatment centers in Rhode Island.

Negatives

• The company reported a net loss attributable to American Shared Hospital Services of $625,000, or $0.10 per share, compared to a net income of $119,000, or $0.02 per diluted share for Q1 2024.
• Gross margin decreased to $942,000 from $2.1 million in the prior year quarter, primarily due to lower treatment volumes.
• Medical equipment leasing revenue decreased to $3.0 million from $4.3 million in the prior year quarter due to lower Gamma Knife and PBRT volumes.
• Total proton beam radiation therapy revenue decreased to $1.6 million from $2.6 million in the prior year quarter.

Risks

• The company faces risks related to economic and market conditions.
• There are risks associated with the variability of financial results between quarters.
• The Gamma Knife, proton therapy, and direct patient care services businesses carry inherent risks.
• Changes to CMS reimbursement rates or reimbursement methodology could negatively impact revenue.
• The timing, financing, and operations of the company's Gamma Knife, proton therapy, and direct patient care services businesses pose risks.
• Expanding within or into new markets involves risks.
• The integration or continued operation of acquired businesses could adversely affect financial results.
• Current and future acquisitions may negatively affect the company's financial position.

Future Outlook

The company anticipates further recovery in treatment volumes into the back half of the year and expects long-term growth from new facilities and acquisitions. They are also focused on improved operational efficiencies and cost controls to drive future profitability.

Management Comments

• Ray Stachowiak, Executive Chairman, stated that the first quarter was highlighted by double-digit revenue growth stemming from the strength of the business model.
• Ray Stachowiak also mentioned that they have already begun to see an increase in treatment volumes in April and expect to see further recovery into the back half of this year.
• Gary Delanois, Chief Executive Officer, added that they continue to see positive momentum building as their growth strategy takes hold and they focus beyond their traditional leasing model to a direct provider of radiation therapy treatment services to cancer patients.

Industry Context

The announcement reflects a trend in the healthcare industry towards consolidation and expansion of cancer treatment services. The company's focus on direct patient care and strategic acquisitions aligns with this trend, as healthcare providers seek to offer comprehensive and integrated services to patients.

Comparison to Industry Standards

• Comparing AMS to competitors like Accuray Incorporated (ARAY) and Varian Medical Systems (VAR), now part of Siemens Healthineers, AMS's revenue growth of 17% in Q1 2025 is competitive.
• However, AMS's net loss contrasts with the profitability often seen in larger, more diversified companies in the medical equipment and services sector.
• The 224% increase in direct patient services revenue is notable, suggesting a successful shift in business strategy, but the overall adjusted EBITDA decrease indicates challenges in maintaining profitability during this transition.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased EBITDA, but encouraged by the revenue growth and strategic initiatives.
• Employees may see opportunities for growth and development with the expansion of services and new facilities.
• Customers (cancer treatment centers and health systems) can expect continued access to advanced radiation therapy equipment and services.
• Patients will benefit from expanded access to cancer treatment in convenient local settings.

Next Steps

• The company plans to continue expanding its business model and increasing patient volumes.
• They will focus on operational enhancements to improve efficiency and reduce operating costs.
• The company is exploring additional tuck-in acquisition opportunities and anticipates closing on one this fiscal year.
• The company expects the new Esprit installed in Guadalajara, Mexico to startup in late 2025.
• The company will develop the new radiation therapy treatment centers in Bristol and Johnston, Rhode Island.

Key Dates

Keywords

radiation therapy, proton beam therapy, Gamma Knife, direct patient services, medical equipment leasing, cancer treatment, American Shared Hospital Services, AMS, financial results, revenue, EBITDA, acquisition